Sign inJoin waitlistJoin the waitlist

Moh'd Khushman

Physician · Washington University School of Medicine

Credentials: · · · · · · ·

History

Washington University School of Medicine
2023–Present

Hematology and Medical Oncology
2009–2012
Internal Medicine
2006–2009
University of Jordan Faculty of Medicine
2002–2006

Research

Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications
Scientific Reports · 2019 · 501 citations
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
British Journal of Cancer · 2017 · 229 citations
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Clinical Cancer Research · 2022 · 161 citations

Emil Lou
14 papers
AS
Anthony Shields
12 papers
Heinz-Josef Lenz
10 papers
John Marshall
10 papers
Michael Hall
10 papers
Benjamin Weinberg
9 papers
Darryl Outlaw
8 papers · 4 as a fellow
WK
Wolfgang Korn
8 papers
GW
Grant Williams
7 papers
AG
Axel Grothey
6 papers
CH
Christian Harmon
6 papers
Davendra Sohal
6 papers

Grants

Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $389.7K · University of Alabama at Birmingham
1997–2027

Clinical trials

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Principal investigator · Recruiting · Phase 1
Washington University School of Medicine
2025–2030
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
Principal investigator · Terminated · Phase 1, Phase 2
University of Alabama at Birmingham
2023–2024
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2026
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Site PI · Recruiting · Phase 2, Phase 3
NRG Oncology
2022–2030